These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31818701)

  • 1. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations.
    Zaja F; Carpenedo M; Baratè C; Borchiellini A; Chiurazzi F; Finazzi G; Lucchesi A; Palandri F; Ricco A; Santoro C; Scalzulli PR
    Blood Rev; 2020 May; 41():100647. PubMed ID: 31818701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
    Barlassina A; González-López TJ; Cooper N; Zaja F
    Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
    Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
    Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
    Carpenedo M; Baldacci E; Baratè C; Borchiellini A; Buccisano F; Calvaruso G; Chiurazzi F; Fattizzo B; Giuffrida G; Rossi E; Palandri F; Scalzulli PR; Siragusa SM; Vitucci A; Zaja F
    Ther Adv Hematol; 2021; 12():20406207211048361. PubMed ID: 34646432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
    Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
    Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.
    Rovó A; Cantoni N; Samii K; Rüfer A; Koenen G; Ivic S; Cavanna D; Benz R
    PLoS One; 2022; 17(4):e0267342. PubMed ID: 35446925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
    Qu MM; Liu XN; Liu XG; Feng Q; Liu Y; Zhang X; Liu S; Zhang L; Li GS; Zhu YY; Lv MY; Peng J; Hou M
    Cytokine; 2017 Apr; 92():110-117. PubMed ID: 28142109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
    Song AB; Al-Samkari H
    Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
    Rodeghiero F; Carli G
    Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment.
    Mageau A; Terriou L; Ebbo M; Souchaud-Debouverie O; Orvain C; Graveleau J; Lega JC; Ruivard M; Viallard JF; Cheze S; Dossier A; Bonnotte B; Perlat A; Gobert D; Costedoat-Chalumeau N; Jeandel PY; Dernoncourt A; Michel M; Godeau B; Comont T
    Am J Hematol; 2022 Jan; 97(1):10-17. PubMed ID: 34661954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin Receptor Agonists and Other Second-Line Therapies for Immune Thrombocytopenia: A Narrative Review With a Focus on Drug Access in Canada.
    Britto J; Holbrook A; Sun H; Cserti-Gazdewich C; Prokopchuk-Gauk O; Hsia C; Khamisa K; Yenson PR; Sholzberg M; Olney HJ; Shivakumar S; Jones D; Merkeley H; Costello J; Jamula E; Arnold DM
    Clin Invest Med; 2024 Mar; 47(1):13-22. PubMed ID: 38546381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia.
    Nazy I; Kelton JG; Moore JC; Clare R; Horsewood P; Smith JW; Ivetic N; D'Souza V; Li N; Arnold DM
    Br J Haematol; 2018 Apr; 181(2):234-241. PubMed ID: 29532903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.